Study wrapper · #593
Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.
Editor's note
In rats with heart failure induced by permanent coronary-artery ligation, researchers reported that hexarelin, a synthetic growth hormone-releasing peptide given twice daily for 30 days, was associated with improved left-ventricular function, reduced myocardial remodeling, and lower oxidative stress. Mechanistically they describe upregulated PTEN and suppressed Akt/mTOR signaling. The result adds to a large and fairly consistent body of rodent cardiac work on hexarelin, which is its strongest evidence domain, though still entirely preclinical. Limitations include a single ligation model, modest numbers, and mechanistic inference from a handful of signaling proteins. These are preclinical findings; human trials would be needed before any clinical conclusions can be drawn.
Plain-language abstract
Scientists studied hexarelin, a lab-made peptide, in rats with heart failure caused by permanently tying off a coronary artery to trigger a heart attack. Rats received injections of hexarelin or salt water twice a day for 30 days. Compared with untreated animals, hexarelin-treated rats had better heart pumping function, less harmful remodeling of the heart muscle, and lower oxidative stress. The researchers linked these effects to changes in internal signaling molecules (more PTEN, less Akt and mTOR activity). The authors conclude hexarelin eased heart-failure damage in this model by acting on those pathways. The abstract reports no adverse events. These are preclinical findings in rats; human research would be needed before drawing any clinical conclusions.